tbuckley/cabot-search huggingface dataset:
Abstract 13139: Sleep Duration, Inflammation and Cardiovascular Mortality in Ambulatory Us Adults: Insights From the National Health and Nutrition Examination Survey
Authors: Kartik Gupta, Shivaraj Nagalli, Rajat Kalra, Mike Pate, Rishab Gupta, Wunan Zhou, Sumanth D Prabhu, Navkaranbir S Bajaj
Journal: Circulation (2020)

Introduction: Sleep disturbance is associated with higher inflammation and cardiovascular mortality. The interplay between sleep duration and inflammation as an effect modifier for cardiovascular risk is unknown. Hypothesis: We sought to evaluate the association between sleep duration, C-reactive protein (CRP), and cardiovascular mortality. Methods: We used data from the National Health and Nutrition Examination Survey (NHANES) 2005-2010 linked with the cause of death data from the National Center for Health Statistics for adults aged ≥18 years. The associations between short (&lt;6 hours), adequate (6-9 hours), and long (&gt;9 hours) sleep duration with inflammation (CRP) and cardiovascular mortality were explored using linear, Poisson and Cox proportional hazard modeling. Results: There were 17,635 eligible participants. The mean age was 47.5±19.2 years with 51% women and 47% self-identified non-Hispanic Whites. There were 2,755 (15.6%), 14,340 (81.3%), and 540 (3.1%) participants in the short, adequate, and long sleep duration groups, respectively. There were 60 (2.2%), 268 (1.9%), and 22 (4.1%) cardiovascular deaths in the short, adequate, and long sleep duration groups, respectively. The adjusted hazard of cardiovascular mortality was 24% (hazard ratio [HR] 1.24, 95% confidence interval [CI] 1.05-1.47, p=0.012) and 78% (HR 1.78, 95% CI 1.37, 2.30, p&lt;0.001) higher among participants with short and long sleep duration, respectively, compared to adequate sleep duration (Figure, panel A). A similar U-shaped trend was observed between log-transformed CRP with higher CRP among participants with short (b=0.06, p=0.01) and long (b=0.26, p&lt;0.001) sleep duration versus adequate sleep duration (Figure, panel B). Conclusions: Short and long sleep duration are independently associated with a higher hazard of cardiovascular mortality and CRP. These findings suggest an association between circadian rhythm, mortality, and inflammation.
Basophils promote barrier dysfunction and resolution in the atopic skin
Authors: Christophe Pellefigues, Karmella Naidoo, Palak Mehta, Alfonso J. Schmidt, Ferdinand Jagot, Elsa Roussel, Alissa Cait, Bibek Yumnam, Sally Chappell, Kimberley Meijlink, Mali Camberis, Jean X. Jiang, Gavin Painter, Kara Filbey, Özge Uluçkan, Olivier Gasser, Graham Le Gros
Journal: Journal of Allergy and Clinical Immunology (2021)
The SPARC-1 trial: A phase I study of neoadjuvant combination interleukin-1 beta and PD-1 blockade in localized clear cell renal cell carcinoma.
Authors: Matthew Dallos, David Henry Aggen, Casey Ager, Aleksandar Obradovic, Clara A Easterlin, Jessica Hawley, Emerson A. Lim, Mark N. Stein, Charles G. Drake
Journal: Journal of Clinical Oncology (2021)

TPS373 Background: Immune checkpoint blockade has significantly improved outcomes for patients with renal cell carcinoma (RCC) in the metastatic setting. However, there is currently no neoadjuvant systemic therapy that improves outcomes for patients with localized RCC. Emerging data suggests that immunosuppressive myeloid cell populations within the tumor microenvironment (TME) represent a key mechanism of adaptive immune resistance. In pre-clinical models, targeting interleukin 1 beta (IL-1beta) can successfully re-establish anti-tumor immunity by shifting the myeloid cells towards M1-like tumor associated macrophages (TAM) and decreasing infiltration of immunosuppressive myeloid-derived suppressor cells (MDSCs). The SPARC-1 study is testing the hypothesis that neoadjuvant therapy with combined IL-1beta blockade (canakinumab) plus PD-1 blockade (spartalizumab) is safe and can successfully remodel the myeloid compartment towards a pro-inflammatory state in patients with localized RCC. Methods: This is a single-center, single-arm, phase I trial of patients with localized clear cell RCC (ccRCC) planned for nephrectomy (stage T1b-T4NanyM0). 14 patients will receive immunotherapy with combination canakinumab (300mg IV) plus spartalizumab (400mg IV) every 4 weeks x 2 doses given 6 weeks prior to nephrectomy. The primary endpoints are safety and feasibility. Secondary endpoints include tumor CD8 T cell infiltration, tumor MDSC infiltration and objective response rate. SPARC-1 offers a unique opportunity to utilize fresh tumor tissue to identify changes in the immune TME with single-cell discrimination following therapy. Therefore, correlative studies will include single-cell RNA-sequencing, multi-color flow cytometry and multiplexed immunofluorescence to quantify changes in the density and spatial proximity of distinct immune cell populations within the TME. The study is open with 4 patient currently enrolled at the time of submission. Clinical trial information: NCT04028245 .
Examining and Modulating Neural Circuits in Psychiatric Disorders With Transcranial Magnetic Stimulation and Electroencephalography: Present Practices and Future Developments
Authors: Fabio Ferrarelli, Mary L. Phillips
Journal: American Journal of Psychiatry (2021)

Transcranial magnetic stimulation (TMS) is a noninvasive brain stimulation technique uniquely equipped to both examine and modulate neural systems and related cognitive and behavioral functions in humans. As an examination tool, TMS can be used in combination with EEG (TMS-EEG) to elucidate directly, objectively, and noninvasively the intrinsic properties of a specific cortical region, including excitation, inhibition, reactivity, and oscillatory activity, irrespective of the individual’s conscious effort. Additionally, when applied in repetitive patterns, TMS has been shown to modulate brain networks in healthy individuals, as well as ameliorate symptoms in individuals with psychiatric disorders. The key role of TMS in assessing and modulating neural dysfunctions and associated clinical and cognitive deficits in psychiatric populations is therefore becoming increasingly evident. In this article, the authors review TMS-EEG studies in schizophrenia and mood disorders, as most TMS-EEG studies to date have focused on individuals with these disorders. The authors present the evidence on the efficacy of repetitive TMS (rTMS) and theta burst stimulation (TBS), when targeting specific cortical areas, in modulating neural circuits and ameliorating symptoms and abnormal behaviors in individuals with psychiatric disorders, especially when informed by resting-state and task-related neuroimaging measures. Examples of how the combination of TMS-EEG assessments and rTMS and TBS paradigms can be utilized to both characterize and modulate neural circuit alterations in individuals with psychiatric disorders are also provided. This approach, along with the evaluation of the behavioral effects of TMS-related neuromodulation, has the potential to lead to the development of more effective and personalized interventions for individuals with psychiatric disorders.
Gastrointestinal sequelae 90 days after discharge for COVID-19
Authors: Jingrong Weng, Yichen Li, Jie Li, Lihan Shen, Lixin Zhu, Yufan Liang, Xutao Lin, Na Jiao, Sijing Cheng, Yibo Huang, Yifeng Zou, Guangjun Yan, Ruixin Zhu, Ping Lan
Journal: The Lancet. Gastroenterology & hepatology (2021)
Novel self-amplificatory loop between T cells and tenocytes as a driver of chronicity in tendon disease
Authors: Emma Garcia-Melchor, Giacomo Cafaro, Lucy MacDonald, Lindsay A N Crowe, Shatakshi Sood, Michael McLean, Umberto G Fazzi, Iain B McInnes, Moeed Akbar, Neal L Millar
Journal: Annals of the Rheumatic Diseases (2021)

Objectives Increasing evidence suggests that inflammatory mechanisms play a key role in chronic tendon disease. After observing T cell signatures in human tendinopathy, we explored the interaction between T cells and tendon stromal cells or tenocytes to define their functional contribution to tissue remodelling and inflammation amplification and hence disease perpetuation. Methods T cells were quantified and characterised in healthy and tendinopathic tissues by flow cytometry (FACS), imaging mass cytometry (IMC) and single cell RNA-seq. Tenocyte activation induced by conditioned media from primary damaged tendon or interleukin-1β was evaluated by qPCR. The role of tenocytes in regulating T cell migration was interrogated in a standard transwell membrane system. T cell activation (cell surface markers by FACS and cytokine release by ELISA) and changes in gene expression in tenocytes (qPCR) were assessed in cocultures of T cells and explanted tenocytes. Results Significant quantitative differences were observed in healthy compared with tendinopathic tissues. IMC showed T cells in close proximity to tenocytes, suggesting tenocyte–T cell interactions. On activation, tenocytes upregulated inflammatory cytokines, chemokines and adhesion molecules implicated in T cell recruitment and activation. Conditioned media from activated tenocytes induced T cell migration and coculture of tenocytes with T cells resulted in reciprocal activation of T cells. In turn, these activated T cells upregulated production of inflammatory mediators in tenocytes, while increasing the pathogenic collagen 3/collagen 1 ratio. Conclusions Interaction between T cells and tenocytes induces the expression of inflammatory cytokines/chemokines in tenocytes, alters collagen composition favouring collagen 3 and self-amplifies T cell activation via an auto-regulatory feedback loop. Selectively targeting this adaptive/stromal interface may provide novel translational strategies in the management of human tendon disorders.
Abstract 15073: Efficacy and Safety of High Intensity Atorvastatin in Patients With Acute Myocardial Infartion Compared to High Intensity Rosuvastatin
Authors: Cheol Ung Choi, Jah Yeon Choi, Byoung Geol Choi, Yoonjee Park, Dong Oh Kang, Won Young Jang, Woohyeun Kim, Seung-young Roh, Jin Oh Na, Jin Won Kim, Eung Ju Kim, Seung Woon W Rha, Chang Gyu Park, Hong Seog Seo, Myung Ho Jeong
Journal: Circulation (2019)

Introduction: Although the use of high intensity statin is recommanded in patients with acute myocardial infarction (AMI) for secondary prevention, there has been consistent concern regarding its a...
Vaccination plus Decarceration — Stopping Covid-19 in Jails and Prisons
Authors: Benjamin A. Barsky, Eric Reinhart, Paul Farmer, Salmaan Keshavjee
Journal: New England Journal of Medicine (2021)

Vaccination plus Decarceration With the rollout of Covid vaccines, public debate regarding health in jails and prisons has increasingly shifted from decarceration toward vaccination of incarcerated...
Skin cancer screening using total body photography and digital dermoscopy: A pilot study among Florida firefighters
Authors: Rachel Fayne, Mahtab Forouzandeh, Valeria De Bedout, Joshua D. Fox, Mina Zarei, Alyx Rosen, Lilia Fernandez, Claudia Genaro, Feng Miao, Tulay Koru-Sengul, Alberto Caban-Martinez, Robert S. Kirsner, Natasha Schaefer Solle, Natalia Jaimes
Journal: Journal of the American Academy of Dermatology (2021)
Abstract PO-039: Artificial intelligence-based extracapsular extension prediction in head and neck cancer analysis
Authors: Yibin Wang, William N. Duggar, Toms V. Thomas, Paul Roberts, Linkan Bian, Haifeng Wang
Journal: Clinical Cancer Research (2021)

Abstract Extracapsular extension (ECE) is a decisive indication for treatment planning of patients with head and neck squamous cell carcinoma (HNSCC). ECE occurs when metastatic tumor cells within the lymph node break through the nodal capsule into surrounding tissues. It is crucial to identify whether ECE occurs in HNSCC patient treatment. Current ECE detection practice mainly relies on the visual identification of doctors and professionals, which can be extremely labor intensive and time-consuming. Therefore, we aim to automatically perform ECE detection using a machine learning technique to classify whether ECE appears or not. In this research, we propose a systematic machine learning approach to detect ECE from 3D computed tomography (CT) scans. The process includes four steps: 1) apply sliding-cube to extract small 3D samples from patient data; 2) various 3D features are extracted for each sample; and 3) three machine learning models, gradient boosting (GB), random forest (RF), and support vector machine (SVM), with feature extraction and selection approaches, are employed for sample classification task; 4) classify the patient based on sample classification result. Different training scenarios are designed for the experimental test. Based on five-fold cross-validation, the experimental results have demonstrated that our model is able to classify ECE and non-ECE patients. To check the explainability of the models, feature analysis is also conducted. The outcome of this research is expected to promote the implementation of artificial intelligence for ECE classification and detection as well as head and neck cancer diagnosis in the radiology computer vision field. Citation Format: Yibin Wang, William N. Duggar, Toms V. Thomas, Paul Roberts, Linkan Bian, Haifeng Wang. Artificial intelligence-based extracapsular extension prediction in head and neck cancer analysis [abstract]. In: Proceedings of the AACR Virtual Special Conference on Artificial Intelligence, Diagnosis, and Imaging; 2021 Jan 13-14. Philadelphia (PA): AACR; Clin Cancer Res 2021;27(5_Suppl):Abstract nr PO-039.
Real-world comparison of abiraterone (A) versus enzalutamide (E) for first-line therapy of metastatic castration-resistant prostate cancer (mCRPC).
Authors: Juan Rodrigo Briones Carvajal, Mahdi Farzad Naimi, Liying Zhang, Urban Emmenegger
Journal: Journal of Clinical Oncology (2021)

133 Background: Second generation androgen receptor signaling inhibitors such as A and E are commonly used first-line treatment options for mCRPC. While differences in the side effect profile of these agents are well documented, there are no predictive markers of response to A versus E, and there is a paucity of comparative outcome data. Methods: We conducted a retrospective exploratory analysis of 100 mCRPC patients (pts) treated at Odette Cancer Centre (Toronto, ON, Canada) between August 2012 and June 2020 with either A (n = 50) or E (n = 50). Pts undergoing first-line mCRPC therapy were randomly selected from a list of 327 A and 254 E patients. Following extraction of disease and pt characteristics, as well as outcome data, we applied the Wilcoxon rank-sum nonparametric test or the Fisher exact test for continuous or categorical variables, respectively, for between group comparisons. For time to event analyses, we created Kaplan-Meier (KM) curves with log-rank testing. Two-sided p-values &lt; 0.05 were considered significant. Results: The A and E cohorts were comparable regarding diagnostic PSA, Gleason score categories, and treatments prior to presentation with mCRPC. The median time to CRPC in the A cohort was 23.3 (95%CI 15.6-29.9) months, compared to 24.1 (19.4-37.4) months in the E cohort (p = 0.942). At initiation of A or E therapy both the median (Q1,Q3) age (77(70,82) vs 76(69,81) years) and median Charlson Comorbidity Index (10(9,11) vs 10(9,11)) were similar (p = 0.469 and p = 0.736, respectively). The rate of diabetes was significantly lower in the A group (8% vs 38%; p &lt; 0.001), but there were no significant differences in cardiovascular comorbidities. Pts starting A therapy had a higher rate of bone metastasis (92% vs 68%; p = 0.005); otherwise, the metastatic pattern did not differ. The median PSA at start of A was 46.75 (13.77,176.80), compared to 27.07 (8.64,136.20) in the E group (p = 0.218). Baseline ALP, hemoglobin and albumin were all comparable. Median follow-up was 13.7 (8.3,26.3) and 19.5 (9.8,34.0) months in the A and E groups (p = 0.091). 38% of A pts and 44% of E pts went on to further lines of systemic therapy upon progression (p = 0.685). The median time to next line of systemic therapy was 11.3 (95%CI 8.3-15.9) months for the A cohort and 12.7 (9.7-16.6) for the E cohort (p = 0.844). The actuarial median overall survival from KM estimations was 35.7 (20.4-52.5) months for the A group, and 34.0 (25.7-38.0) months for the E group. Conclusions: In men undergoing first-line A or E therapy for mCRPC, time to next line of systemic therapy and overall survival did not differ significantly, while baseline pt and disease characteristics were largely similar. A substantial number of pts do not receive ≥2 lines of therapy for mCRPC under real-world circumstances.
Prediction model for brain metastasis (BM) in patients with metastatic germ-cell tumors (mGCT) accounting for size of pulmonary metastases.
Authors: Ryan Ashkar, Sandra K. Althouse, Clint Cary, Timothy A. Masterson, Richard Foster, Nasser H. Hanna, Lawrence H. Einhorn, Nabil Adra
Journal: Journal of Clinical Oncology (2021)

378 Background: BM is an independent adverse prognostic factor that can lead to treatment complications and failure in pts with mGCT. We aimed to establish an effective and practical BM prediction model accounting for size of pulmonary metastases. Methods: 2,291 consecutive pts with mGCT treated at Indiana University between January 1990 and September 2017 were identified. Pts were divided into 2 categories: BM present (N=154) and BM absent (N=2137). Kaplan-Meier methods were used to analyze progression free survival (PFS) and overall survival (OS). Logistic regression was used to determine a predictive model for whether BM was present. The data was separated 50/50 into training and validation datasets with equal numbers of events in each. Size of pulmonary metastases were calculated based on the sum of long axis diameter of pulmonary metastases for each patient and were divided into &lt;3cm vs. ≥3cm. Results: Baseline characteristics for 2 groups are listed in the table below. 2-yr PFS and OS for pts with vs without BM: 17% vs 65% (p&lt;0.001) and 62% vs 91% (p&lt;0.001) respectively. Among the 154 pts with BM, 64 (42%) had radiation only (whole-brain radiotherapy or gamma knife), 22 (14%) had BM-surgery only, 14 (9%) had both radiation and BM-surgery. 54 pts (35%) did not receive local therapy for BM. A stepwise selection was used to determine the best model with p&lt;0.15 as the entry and staying criteria. The model with the largest ROC AUC was used moving forward. The model was tested in the validation dataset. A model was generated including age at diagnosis≥40 (1 point), pre-chemotherapy hCG≥5000 (1 point), presence of bone metastases (1 point), choriocarcinoma predominant histology (2 points), and presence of pulmonary metastases size &lt;3 cm (2 points) or ≥3 cm (3 points). Patients with 0 points had a 0.6% probability of having BM, 1 point → 1.4%, 2 points → 3.5%, 3 points → 8.2%, 4 points → 18.3%, 5 points → 36%, 6 points → 58%, 7 points → 78%, and 8 points → 90%. Conclusions: The prediction model developed in this study demonstrated discrimination capability of predicting BM occurrence in mGCT and can be used by clinicians to identify high-risk pts. [Table: see text]
Unusual cause of abdominal pain and papule
Authors: He Zhou, Fenrong Chen, Jiayao Wang, Xin Liu, Jie Liang
Journal: Gut (2021)

A 45-year-old man developed multiple papules on the abdomen (with sizes of about 2–15 mm) for 9 months (figure 1), intermittent black stool and abdominal pain for 5 months. Colonoscopy revealed chronic inflammation of the colorectal mucosa (pathological results indicated active inflammation of the mucosa and Epstein-Barr virus positive) (figure 2). CT enterography examinations revealed segmental ileal stenosis in the right lower abdomen. The abdominal pain worsened 3 days before admission. Laboratory examinations during hospitalisation showed that C reactive protein was 31.53 ng/L; fibrinogen was 5.77 g/L and D-dimer was 1308 ng/mL, respectively. On the day of hospitalisation, the patient had sudden aggravation of abdominal pain without flatus and defecation. Physical examination showed abdominal tenderness, rebound pain and muscle tension. Abdominal X-ray indicated intestinal obstruction. Emergency laparotomy was performed. During the operation, a large number of gas, yellow …
Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial
Authors: Nathalie De Castro, Olivier Marcy, Corine Chazallon, Eugène Messou, Serge Eholié, Jean-Baptiste N'takpe, Nilesh Bhatt, Celso Khosa, Isabel Timana Massango, Didier Laureillard, Giang Do Chau, Anaïs Domergue, Valdilea Veloso, Rodrigo Escada, Sandra Wagner Cardoso, Constance Delaugerre, Xavier Anglaret, Jean-Michel Molina, Beatriz Grinsztejn, Ahyi Irmine, Aka Kakou, Alves Ana cláudia, Amani Jacqueline, Amoakon Bonzou, Anglaret Xavier, Anzian Amani, Azam Khalide, Barreto Débora Faber, Bastos dos Santos Rui, Beuscart Aurélie, Bhatt Nilesh, Bi Antoine, Bonnet Maryline, Bui thi Kim Nhung, Camacho Luiz, Cao Tung khanh, Chazallon Corine, Coelho Lara, Cong thi Mai Luong, Da SILVA Robson Pierre, Dang thi Minh Há, Dano Lehi Florence, De castro Nathalie, De Solère Marie, Delaugerre Constance, Diallo Alpha, Dinh phuong Thanh, Diomandé Donald, Do cha Giang, Do ha thanh Trang, Domergue Anaïs, Dong bui vu hoang Trang Quynh Nhu, Eboumou Fulgence, Eholie Serge, Ello Frederick, Emieme Arlette, Escada Rodrigo, Etilé Etienne, Fanny Salimata, Ferreira Ana cristina, Gbey Robert, Gnokoro Joachim, Gomes Tatiane, Gonzales Maura lassance, Grinsztejn Beatriz, Guiroy Frederique, Ha Thanh Trang Do, Hoagland Brenda, Huynh Anh Phuong, Huynh hoang Khanh thu, Irié Marcelin, Kacou Jean-claude, Kan Samuel, Karcher Sophie, Kassy Mc, Khosa Celso, Konan Lambert, Konan Romuald, Koné Fatoumata, Kouadio Suzanne, Kouamé Martin, Krsitic Tânia, Labibi Georgette, Laureillard Didier, Le Carrou Jérôme, Le Guoc Khanh, Le Thi Ngoc bich, Lessa Flávia, Long Van Duong, Luong Anh Que, Mai Huyen Thi Thu, Mai Thu Huyen Nguyet, Manhiça Emelva, Marcy Olivier, Marins Luana, Matsinhe Lectícia, Menan Hervé, Messou Eugène, Molina Jean-michel, Montoyo Alice, Moreira Ronaldo ismerio, N'takpé Jean-baptiste, Nazer Sandro, Nguyen Cao van thi, Nguyen Nuoi THI, Nguyen duc Bang, Nguyen huu Lân, Nguyen ngoc Lan, Nguyen nhu Viet, Nguyen thi Hong, Nhumaio Dilário, Pham Hang THU, Pham Anh THI QUYNH, Ponscarme Diane, Previllon Miresta, Rabe Cyprien, Rapoud Delphine, Rebelo Daniel, Rekacewicz Claire, Ribeiro Valéria rita, Ribeiro Jorge, Salgado Lucimar, Santana de MOURA Soraia, Santos Desiree, Siloue Yamissa, Siloue Bertine, Sitoe Nádia, Taburet Anne-marie, Tavares Isabel cristina, Tavora dos Santos Filho Ezio, Tchehy Cecile, Timana Isabel, Toni Thomas-d'aquin, Torres Thiago, Tran Thao PHAM PHUONG, Tran Loc HUU, Tran Quy Thi Kim, Tran Tien Thi Thuy, Tran Ton, Tran Thi Hieu Nhi, Tran Thi-Hai Ly, Veloso Valdilea, Vilanculo Arlindo, Vu Xuan Thinh, Vubil Adolfo, Wagner Sandra, Zitha Alcina, None Astrid
Journal: The Lancet Infectious Diseases (2021)
A prognostic survival model based on metabolism-related gene expression in plasma cell myeloma
Authors: Han-ying Huang, Yun Wang, Wei-da Wang, Xiao-li Wei, Robert Peter Gale, Jin-yuan Li, Qian-yi Zhang, Ling-ling Shu, Liang Li, Juan Li, Huan-xin Lin, Yang Liang
Journal: Leukemia (2021)